Location · Illinois
Clinical trials recruiting in Illinois
890 recruiting studies have at least one site in Illinois; 285 accept healthy volunteers. Studies that need a specific condition are included too, so check each listing.
Want the research companies that run paid Phase 1 studies for healthy volunteers? Paid clinical trial companies in Illinois.
890 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Chicago, IL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Chicago, IL + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Chicago, IL + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Merck Sharp & Dohme LLC
- Location
- Chicago, IL + 70 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
- Location
- Chicago, IL + 7 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA
- Location
- Chicago, IL + 9 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Bristol-Myers Squibb
- Location
- Chicago, IL + 18 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Takeda
- Location
- Chicago, IL + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen
- Location
- Chicago, IL + 3 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
Pfizer
- Location
- Chicago, IL + 27 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular…
AbbVie
- Location
- Oak Lawn, IL + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Merck Sharp & Dohme LLC
- Location
- Chicago, IL + 35 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Sanofi
- Location
- Chicago, IL + 118 other US sites
- Eligibility basics
- Ages 16–80
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Champaign, IL + 70 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Biogen
- Location
- Chicago, IL + 24 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Biogen
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 0 mo–1 mo
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Renibus Therapeutics, Inc.
- Location
- Chicago, IL + 26 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Novartis Pharmaceuticals
- Location
- Chicago, IL + 19 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Rolling Meadows, IL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
COMPASS Pathways
- Location
- Chicago, IL + 8 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Skokie, IL + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Definium Therapeutics US, Inc.
- Location
- Chicago, IL + 22 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study of MZE782 in Adults With PKU
Maze Therapeutics
- Location
- Chicago, IL + 6 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- O'Fallon, IL + 14 other US sites
- Eligibility basics
- Ages 18–75